#USA #Cranbury #Porton Advanced #UC-MSCs #Exosome Manufacturing

Porton Advanced Achieves FDA Drug Master File Acceptance for UC-MSCs Cell Bank

Introduction
In a significant milestone for the field of exosome therapeutics, Porton Advanced recently announced the acceptance of its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for filing with the U.S. FDA's Center for Biologics Evaluation and Research (CBER). This acceptance under Drug Master File (DMF) #32973 not only enhances Porton Advanced’s position in a rapidly evolving market but also serves as a fundamental step for partners focusing on exosome-based therapies.

The Impact of FDA Acceptance
The acceptance of the DMF is a pivotal achievement for Porton Advanced, providing a well-structured framework for sponsors engaged in exosome programs. By allowing them to reference DMF #32973 in their regulatory submissions, the filing accelerates the review process of their applications by the FDA. This can lead to less duplicated documentation and streamlined pathways to market for innovative therapies that use exosomes.

Innovative Manufacturing Platform
Porton Advanced operates a Good Manufacturing Practice (GMP)-compliant platform specialized for cell and gene therapy that incorporates advanced manufacturing and rigorous quality control systems. This state-of-the-art approach ensures high purity, maximizes activity, and enhances the stability of exosome products. Key features include:

• - Flexible Cell Culture Systems:

Capable of supporting various cell lines such as HEK293, MSC, K562, and induced pluripotent stem cells (iPSCs), enabling sponsors to choose the most suitable cell source for their therapeutic needs.

• - Scalable and Robust Processes:

Bioreactor systems that range from 2L to 50L, facilitating a smooth transition from research and development to commercial production.

• - High Yield:

The process delivers exosome product concentrations of greater than or equal to 1E+11 particles/mL, optimizing production efficiency.

• - Rapid Delivery:

GMP-grade exosomes are available within a month, enabling faster progression for clients ready to enter clinical phases.

• - Stringent Quality Control Testing:

Comprehensive assessments covering identity, purity, potency, and safety to ensure consistency across batches.

Revolutionizing Drug Development and Regenerative Medicine
The regulatory acceptance for the UC-MSCs cell bank stands as a crucial enabler for Porton Advanced's global partners looking to propel exosome-based initiatives into the marketplace. The company emphasizes its commitment to advancing the applications of exosome technology in drug development, offering integrated services that range from raw material customization all the way to formulation development.

About Porton Advanced
Porton Advanced Solutions is a standout subsidiary of Porton Pharma Solutions, recognized for being a prominent Contract Development and Manufacturing Organization (CDMO). With its headquarters in Cranbury, New Jersey, and two GMP facilities in Suzhou, China, Porton Advanced specializes in delivering comprehensive solutions for Advanced Therapy Medicinal Products (ATMPs). The company provides an extensive range of services, from cell banking, process and analytical method development to cGMP production and fill-finish services, supporting various stages of drug development from early research up to commercialization.

Currently equipped with 215,000 sq ft of GMP-compliant facilities, Porton Advanced hosts multiple viral vector production lines and cell therapy production suites, successfully aiding its clients in obtaining 26 global Investigational New Drug (IND) approvals across major regulatory authorities like NMPA, FDA, and Medsafe. With ongoing Phase I/II ATMP projects and dedicated resources for overseas clinical-stage pipelines, Porton Advanced exemplifies a client-centric approach designed to expedite access to innovative therapies.

Conclusion
By enhancing its manufacturing capabilities and achieving FDA Drug Master File acceptance, Porton Advanced is not only improving its service offering but is also positioning itself as a leader in the exosome therapeutics landscape. As it continues to evolve and expand its services, Porton Advanced remains dedicated to facilitating timely access to effective treatments for patients worldwide.